Population-based cohort study of survival impact of non-adherence to adjuvant endocrine therapy for breast cancer
Dr. Theodoros Foukakis
Adjuvant endocrine therapy (AET) combining gonadotropin-releasing hormone analogues (GnRHa) with tamoxifen (TAM) or aromatase inhibitors (AI) improves survival in premenopausal women with endocrine-positive breast cancer compared to TAM and is increasingly prescribed. However, there are concerns regarding adherence. A population-based cohort study in Sweden found that adherence was lower to combination regimens than to single AET, and non-adherence was associated with poorer invasive breast cancer –free survival.
